Twist Bioscience Corporation $TWST Stock Holdings Lifted by Oddo BHF Asset Management Sas

Oddo BHF Asset Management Sas grew its position in Twist Bioscience Corporation (NASDAQ:TWST) by 7.6% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 145,960 shares of the company’s stock after purchasing an additional 10,310 shares during the period. Oddo BHF Asset Management Sas owned about 0.23% of Twist Bioscience worth $6,936,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in TWST. William Blair Investment Management LLC increased its holdings in Twist Bioscience by 43.7% in the fourth quarter. William Blair Investment Management LLC now owns 5,954,429 shares of the company’s stock worth $188,874,000 after buying an additional 1,812,146 shares during the last quarter. EdgePoint Investment Group Inc. lifted its stake in Twist Bioscience by 31.7% in the fourth quarter. EdgePoint Investment Group Inc. now owns 5,377,991 shares of the company’s stock valued at $170,590,000 after acquiring an additional 1,295,672 shares during the last quarter. Millennium Management LLC grew its position in Twist Bioscience by 151.5% in the third quarter. Millennium Management LLC now owns 1,793,850 shares of the company’s stock worth $50,479,000 after acquiring an additional 1,080,722 shares in the last quarter. ARK Investment Management LLC grew its position in Twist Bioscience by 12.4% in the fourth quarter. ARK Investment Management LLC now owns 7,559,495 shares of the company’s stock worth $239,787,000 after acquiring an additional 832,687 shares in the last quarter. Finally, Balyasny Asset Management L.P. raised its holdings in shares of Twist Bioscience by 934.0% during the 2nd quarter. Balyasny Asset Management L.P. now owns 628,241 shares of the company’s stock valued at $23,113,000 after purchasing an additional 567,481 shares in the last quarter.

Twist Bioscience Stock Performance

Shares of TWST opened at $85.47 on Thursday. The company has a market capitalization of $5.32 billion, a PE ratio of -64.26 and a beta of 2.11. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.70 and a quick ratio of 2.42. Twist Bioscience Corporation has a one year low of $23.30 and a one year high of $105.47. The company’s fifty day moving average price is $83.72 and its 200 day moving average price is $61.36.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Monday, May 4th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.22). The firm had revenue of $110.72 million for the quarter, compared to the consensus estimate of $107.64 million. Twist Bioscience had a negative net margin of 19.85% and a negative return on equity of 26.73%. The firm’s revenue was up 19.3% on a year-over-year basis. During the same quarter last year, the company earned ($0.66) earnings per share. As a group, analysts expect that Twist Bioscience Corporation will post -2.02 earnings per share for the current year.

Insider Buying and Selling

In other news, SVP Paula Green sold 291 shares of the stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $87.32, for a total value of $25,410.12. Following the completion of the sale, the senior vice president directly owned 120,414 shares of the company’s stock, valued at approximately $10,514,550.48. This represents a 0.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Dennis Cho sold 14,205 shares of the firm’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $89.75, for a total transaction of $1,274,898.75. Following the completion of the sale, the insider owned 105,141 shares in the company, valued at approximately $9,436,404.75. The trade was a 11.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 50,211 shares of company stock worth $4,199,331. 3.08% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on TWST shares. Guggenheim upped their price objective on shares of Twist Bioscience from $60.00 to $107.00 and gave the stock a “buy” rating in a report on Monday, June 29th. Canaccord Genuity Group boosted their price target on Twist Bioscience from $90.00 to $120.00 and gave the stock a “buy” rating in a research report on Tuesday, July 14th. Piper Sandler started coverage on Twist Bioscience in a research note on Thursday, June 11th. They set an “overweight” rating and a $85.00 price target for the company. TD Cowen raised their price objective on Twist Bioscience from $68.00 to $89.00 and gave the company a “buy” rating in a research note on Monday, June 15th. Finally, Robert W. Baird boosted their target price on Twist Bioscience from $50.00 to $65.00 and gave the stock an “outperform” rating in a report on Tuesday, May 5th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $90.30.

Twist Bioscience Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.